WEKO3
インデックスリンク
アイテム
Short-term outcomes of neoadjuvant chemotherapy with capecitabine plus oxaliplatin for patients with locally advanced rectal cancer followed by total or tumor-specific mesorectal excision with or without lateral pelvic lymph node dissection
https://fmu.repo.nii.ac.jp/records/2002048
https://fmu.repo.nii.ac.jp/records/200204861143d1a-beaa-4d30-af67-f9281b9cb44c
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
FksmJMedSci_68_p89.pdf (249.2 KB)
|
|
| Item type | デフォルトアイテムタイプ（フル）fmu(1) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2022-08-23 | |||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||
| タイトル | Short-term outcomes of neoadjuvant chemotherapy with capecitabine plus oxaliplatin for patients with locally advanced rectal cancer followed by total or tumor-specific mesorectal excision with or without lateral pelvic lymph node dissection | |||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||
| 作成者 |
Sakamoto, Wataru
× Sakamoto, Wataru
× Kanke, Yasuyuki
× Onozawa, Hisashi
× Okayama, Hirokazu
× Endo, Hisahito
× Fujita, Shotaro
× Saito, Motonobu
× Saze, Zenichiro
× Momma, Tomoyuki
× Kono, Koji
|
|||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||
| 権利情報Resource | https://creativecommons.org/licenses/by-nc-sa/4.0/ | |||||||||||||||||||||||||
| 権利情報 | © 2022 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. | |||||||||||||||||||||||||
| 内容記述 | ||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||
| 内容記述 | Background: The standard strategy in Japan for locally advanced rectal cancer is total mesorectal excision plus adjuvant chemotherapy. However, large tumors significantly restrict pelvic manipulation of the distal side of the tumor during surgery;therefore, from an oncological point of view, it is better to shrink the tumor as much as possible preoperatively to optimize the circumferential resection margin. In recent years, advances in systemic chemotherapy have significantly improved the tumor reduction effect, enabling such drug therapy prior to surgery for locally advanced rectal cancer. We herein retrospectively evaluated the clinical, short-term outcomes of patients treated by neoadjuvant chemotherapy (NAC) using capecitabin and oxaliplatin (CAPOX), focusing on overall safety as well as clinical and pathological staging responses to NAC. Methods: We applied the preoperative chemotherapy protocol to T3-4, any N, M0 or M1a (with resectable metastases) (UICC 8th) Ra/Rb rectal cancers. The chemotherapy regimen consisted of four cycles of CAPOX. After NAC, curative intent surgery with total mesorectal excision/tumor-specific mesorectal excision with/without metastasectomy was performed. Adverse effects (AEs) and compliance with NAC, surgical complications, clinical and pathological staging were evaluated. All patients undergoing the protocol between January 2017 and June 2021 at Fukushima Medical University were enrolled. Results: Twenty cases were enrolled. No severe AEs were observed either preoperatively or perioperatively. Preoperative assessment of NAC showed no cases of progressive disease (PD). Radical resection was achieved in all cases. Histological therapeutic grading after NAC revealed one grade 3, four grade 2, three grade 1b, eleven grade 1a and one grade 0 among all cases. Conclusion: This study suggests that NAC for locally advanced rectal cancer is likely to be acceptable because there were no severe AEs pre- or perioperatively, radical resection was achieved in all cases, and there were no cases of PD. | |||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||
| 出版者 | The Fukushima Society of Medical Science | |||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||
| 書誌情報 |
en : Fukushima Journal of Medical Science 巻 68, 号 2, p. 89-95, 発行日 2022 |
|||||||||||||||||||||||||
| 関連情報 | ||||||||||||||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.5387/fms.2022-07 | |||||||||||||||||||||||||
| 関連情報 | ||||||||||||||||||||||||||
| 識別子タイプ | PMID | |||||||||||||||||||||||||
| 関連識別子 | 35732415 | |||||||||||||||||||||||||
| 関連情報 | ||||||||||||||||||||||||||
| 識別子タイプ | ICHUSHI | |||||||||||||||||||||||||
| 関連識別子 | 2023252940 | |||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||||||||||||
| 収録物識別子 | 0016-2590 | |||||||||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||||||||
| 収録物識別子 | 2185-4610 | |||||||||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||||||||||||||
| 収録物識別子 | AA0065246X | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | Rectal cancer | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | neoadjuvant chemotherapy | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | CAPOX | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | oxaliplatin | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | capecitabine | |||||||||||||||||||||||||
